Caitlin K Gribbin, MD

Publications

3 grants

PI
A phase Ib trial of FHD-286 plus mosunetuzumab in previously treated follicular lymphoma
Follicular Lymphoma Foundation · 2026–2031
FLF 261485-01
Co-I
Interrogating and Targeting ICANS in CAR T-Cell Therapies
National Cancer Institute · 2026–2028
R21CA307817-01A1
PI
Elucidating the role of follicular dendritic cells in EZH2-mutated follicular lymphoma
Lymphoma Research Foundation · 2024–2026
LRF 234088-02

Completed grants (1)

Co-I
Elucidating the role of follicular dendritic cells in EZH2-mutated follicular lymphoma progression and transformation
The Asco Cancer Foundation · 2023–2024
ASCO 226835-01

1 study

PI
BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies
PHASE1 · Eli Lilly and Company · OPEN TO ACCRUAL (as of 2026)
Lymphoma, Non-Hodgkin; B-cell Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, B-cell Marginal Zone; Waldenstrom Macroglobulinemia; Lymphoma, Mantle Cell
NCT07101328

Completed & closed trials (3)

PI
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO)
PHASE1 · Marker Therapeutics, Inc. · CLOSED TO ACCRUAL (as of 2026)
Non-Hodgkin Lymphoma, Adult; Non-Hodgkin Lymphoma, Refractory; Non-Hodgkin Lymphoma, Relapsed; Non Hodgkin Lymphoma; Hodgkin Lymphoma; Hodgkin Lymphoma, Adult; Hodgkin's Lymphoma, Relapsed, Adult
NCT05798897
PI
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-23)
PHASE3 · Kite Pharma, Inc. · CLOSED TO ACCRUAL (as of 2026)
High-risk Large B-cell Lymphoma (LBCL)
NCT05605899
PI
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
PHASE1 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2026)
Follicular Lymphoma; B-Cell Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma
NCT05934838

Kite Pharma, Inc.